Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?
Gustave Roussy, Université Paris-Saclay, Département de Médecine Oncologique, Villejuif, F-94805, France. Electronic address: ducreux@igr.fr.
Michel
M
Ducreux
Gustave Roussy, Université Paris-Saclay, Ligue Nationale Contre le Cancer Meta-analysis Platform, Department of Biostatistics and Epidemiology, INSERM U1018, CESP, Villejuif, F-94805, France.
Jean-Pierre
JP
Pignon
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D000068818:Cetuximab / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D015201:Meta-Analysis as Topic; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D000077544:Panitumumab
D000911:Antibodies, Monoclonal; D000068258:Bevacizumab; D000077544:Panitumumab; D066246:ErbB Receptors; D000068818:Cetuximab